EUROPEAN CURRICULUM VITAE FORMAT

PERSONAL INFORMATION

Name	**MASSON RICCARDO**
E-mail	riccardo.masson@istituto-besta.it
Nationality	Italian
TITLES	MD, CHILD NEUROLOGY AND PSYCHIATRY
	MED LICENSE 05685

WORK EXPERIENCE

• Dates	MAY 2017 (ONGOING)
• Name and address of employer	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy) Developmental Neurology Unit
• Occupation or position held	Consultant in Child Neurology
• Dates	JULY 2016 → APRIL 2017
• Name and address of employer	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy) Developmental Neurology Unit
• Occupation or position held	Research Fellow (in Child Neurology)

EDUCATION AND TRAINING

• Dates	June 2011 → June 2016
• Organization	University of Verona (Verona, Italy)
• Principal subjects	Motor outcome after perinatal stroke: possible prognostic role of quantitative EEG in the first months of life.
• Title of qualification awarded	Specialist in Child Neurology and Psychiatry
• Dates	September 2015 → May 2016
• Organization	IRCCS Stella Maris (Calambrone, Pisa, Italy)
• Principal subjects	Early Infancy Neurology
• Title of qualification awarded	Clinical and Research Stage
• Dates	October 2004 → October 2010
• Organization	University of Verona (Verona, Italy)
• Title of qualification awarded	Degree in Medicine and Surgery

CLINICAL TRIAL EXPERIENCE

• Dates	2020
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101. Principal Investigator.
• Dates	2019 - 2020
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	Retrospective cohort study of the natural history of type 1 spinal muscular atrophy using medical record data. Principal Investigator.

• Dates	From 2018
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	AVXS-101-CL-302: Phase 3 open-label, single-arm, single-dose gene replacement therapy clinical trial for patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies delivering AVXS-101 by intravenous infusion. Principal Investigator.
• Dates	2018
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	A randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of Amifampridine Phosphate in ambulatory patients with Spinal Muscular Atrophy type 3.
• Dates	From 2018
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	Long term safety study of Amifampridine Phosphate in ambulatory patients with Spinal Muscular Atrophy type 3.
• Dates	From 2019
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	DSC/14/2357/48: A randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of Givinostat in ambulant patients with Duchenne Muscular Dystrophy. Phase III. Principal Investigator.
• Dates	From 2018
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	Long term observational study of Translarna safety and effectiveness in usual care. 38145 PTC STRIDE Translarna for Duchenne Muscular Dystrophy. Principal Investigator.
• Dates	2018-2019
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	Duchenne Muscular Dystrophy double-blind randomized trial to find optimum steroid regimen (FOR-DMD).
• Dates	From 2017
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	A two part seamless, open-label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 1 spinal muscular atrophy patients. Principal Investigator.
• Dates	From 2016
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	A two part seamless, multi-center randomized, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy patients. Principal Investigator.
• Dates	2016 - 2020
• Organization	IRCCS C. Besta Neurological Institute Foundation (Milan, Italy)
• Subject	Open-label, multi-part, first-in-human proof of concept study in infants with Type 1 spinal muscular atrophy, to evaluate safety, tolerability, PK, PD and efficacy of oral LMI070. Principal Investigator.

PUBBLICATIONS

2021	Foppiani A, De Amicis R, Leone A, Ravella S, Bedogni G, Battezzati A, D'Amico A, Bertini E, Pedemonte M, Bruno C, Agosto C, Mastella C, Giaquinto E, **Masson R**, Baranello G, Bertoli S, Predictive fat mass equations for spinal muscular atrophy type I children: development and internal validation, Clinical Nutrition, https://doi.org/10.1016/j.clnu.2021.02.026.
2021	Baranello G, Darras BT, Day JW, Deconinck N, Klein A, **Masson R**, Mercuri E, Rose K, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Seabrook T, Fontoura P, Servais L; FIREFISH Working Group. Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med. 2021 Feb 24. doi: 10.1056/NEJMoa2009965. Online ahead of print.
2020	**Masson R**, Brusa C, Scoto M, Baranello G. Brain, cognition and language development in Spinal Muscular Atrophy type 1: a scoping review. Dev Med Child Neurol. 2021 Jan 15. doi: 10.1111/dmcn.14798. Online ahead of print.

2020 Cinquina V, Ciaccio C, Venturini M, **Masson R**, Ritelli M, Colombi M. Expanding the PURA syndrome phenotype: A child with the recurrent PURA p.(Phe233del) pathogenic variant showing similarities with cutis laxa. Mol Genet Genomic Med. 2020 Dec 4;e1562. doi: 10.1002/mgg3.1562.

2020 Maggi L, Brugnoni R, Canioni E et al. Clinical and Molecular Spectrum of Myotonia and Periodic Paralyses Associated With Mutations in SCN4A in a Large Cohort of Italian Patients. Front Neurol. 2020 Jul 29;11:646. doi: 10.3389/fneur.2020.00646.

2020 Ciaccio C, Cellini E, Guerrini R, Pantaleoni C, **Masson R**. Mirror syndromes regarding AKT3 mutations: Loss of function variant leading to microcephaly. Am J Med Genet A . 2020 Aug 21. doi: 10.1002/ajmg.a.61821.

2020 Carneiro MIS, Russo C, **Masson R**, Rossi Sebastiano D, Baranello G, Turati C, Bolognini N. Motor learning in unilateral cerebral palsy and the influence of corticospinal tract reorganization. Eur J Paediatr Neurol. 2020 May 4:S1090-3798(20)30084-2. doi: 10.1016/j.ejpn.2020.04.013.

2020 Bello L, D'Angelo G, Villa M et al. Genetic Modifiers of Respiratory Function in Duchenne Muscular Dystrophy. Ann Clin Transl Neurol. 2020 May;7(5):786-798. doi: 10.1002/acn3.51046.

2020 Bertoli S, De Amicis R, Bedogni G, Foppiani A, Leone A, Ravella S, Mastella C, Baranello G, **Masson R**, Bertini E, D'Amico A, Pedemonte M, Bruno C, Agosto C, Giaquinto E, Bassano M, Battezzati A. Predictive energy equations for spinal muscular atrophy type I children. Am J Clin Nutr. 2020 May 1;111(5):983-996. doi: 10.1093/ajcn/nqaa009.

2020 Baranello G, De Amicis R, Arnoldi MT, Zanin R, Mastella C, **Masson R**, Leone A, Alberti K, Foppiani A, Battezzati A, Bertoli S. Evaluation of body composition as a potential biomarker in spinal muscular atrophy. Muscle Nerve. 2020 Feb 3. doi: 10.1002/mus.26823.

2020 Bonanno S, Marcuzzo S, Malacarne C, Giagnorio E, **Masson R**, Zanin R, Arnoldi MT, Andreetta F, Simoncini O, Venerando A, Gellera C, Pantaleoni C, Mantegazza R, Bernasconi P, Baranello G, Maggi L. Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. Biomedicines. 2020 Jan 26;8(2). pii: E21. doi: 10.3390/biomedicines8020021.

2020 LoMauro A, Mastella C, Alberti K, **Masson R**, Aliverti A, Baranello G. Reply to Chacko et al.: Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy. Am J Respir Crit Care Med. 2020 Mar 1;201(5):624-626. doi: 10.1164/rccm.201910-2022LE.

2019 LoMauro A, Mastella C, Alberti K, **Masson R**, Aliverti A, Baranello G. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy. Am J Respir Crit Care Med. 2019 Aug 21. doi: 10.1164/rccm.201906-1175LE. [Epub ahead of print].

2019 Baranello G, Vai S, Broggi F, **Masson R**, Arnoldi MT, Zanin R, Mastella C, Bianchi ML. Evolution of bone mineral density, bone metabolism and fragility fractures in Spinal Muscular Atrophy (SMA) types 2 and 3. Neuromuscul Disord. 2019 Jun 6. pii: S0960-8966(19)30304-9. doi: 10.1016/j.nmd.2019.06.001. [Epub ahead of print].

2019 Milone R, **Masson R**, Di Cosmo C, et al. A Not So Benign Family Pedigree With Hereditary Chorea: A Broader Phenotypic Expression or Additional Picture? Child Neurol Open. 2019 Feb 12;6:2329048X19828881. doi: 10.1177/2329048X19828881.

2018 Pagliano E, Baranello G, **Masson R**, Foscan M, Arnoldi MT, Marchi A, Aprile G, Pantaleoni C. Outcome measures for children with movement disorders. Eur J Paediatr Neurol. 2018;S1090-3798(17)31694-X. doi:10.1016/j.ejpn.2018.01.014.

2018 **Masson R**, Pagliano E, Baranello G. Classification of cerebral palsy and potential role of video recording. Eur J Paediatr Neurol. 2018;22(1):209-210. doi:10.1016/j.ejpn.2017.10.001.

2017 **Masson R**, Pagliano E, Baranello G. Efficacy of oral pharmacological treatments in dyskinetic cerebral palsy: a systematic review. Dev Med Child Neurol. 2017;59 (12):1237-1248. doi: 10.1111/dmcn.13532.

2017 **Masson R**, Piretti E, Pellegrin S, Gusson E, Poretti A, Valente EM, Cantalupo G. Early-onset head titubation in a child with Poretti-Boltshauser syndrome. Neurology. 2017;88(15):1478-1479. doi:10.1212/WNL.0000000000003823.

2016 | **Masson R**, Guerra S, Cerini R, Pensato V, Gellera C, Taroni F, Simonati A. Early white matter involvement in an infant carrying a novel mutation in ACOX1. European Journal of Paediatric Neurology. 2016;20:431-434. doi: 10.1016/j.ejpn.2016.02.007.

Personal data: I authorize the processing of personal data contained in my curriculum vitae according to the Italian Law n. 196, DL June 30, 2003 and GDPR 679/16.

Milan, 02/03/2021